ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer

William Small, John P. Hayes, W. Warren Suh, Abdel Wahab May, Ross A. Abrams, Nilofer Azad, Prajnan Das, Jadranka Dragovic, Karyn A. Goodman, Salma K. Jabbour, William Jones, Andre A. Konski, Albert C. Koong, Rachit Kumar, Percy Lee, Timothy M. Pawlik, Joseph M. Herman

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The American College of Radiology Appropriateness Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. The panel reviewed the pertinent literature and voted on five variants to establish appropriate recommended treatment of borderline and unresectable pancreatic cancer. The guidelines reviewed the use of radiation, chemotherapy, and surgery. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.

Original languageEnglish (US)
JournalOncology (Williston Park, N.Y.)
Volume30
Issue number7
StatePublished - Jul 1 2016

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Small, W., Hayes, J. P., Suh, W. W., May, A. W., Abrams, R. A., Azad, N., Das, P., Dragovic, J., Goodman, K. A., Jabbour, S. K., Jones, W., Konski, A. A., Koong, A. C., Kumar, R., Lee, P., Pawlik, T. M., & Herman, J. M. (2016). ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer. Oncology (Williston Park, N.Y.), 30(7).